Synaptogenix Inc (SNPX)

[Cyosol]

"FDA Opens New Path for Alzheimer's Treatments"

https://www.bloomberg.com/news/articles/2018-02-15/fda-opens-new-path-for-alzheimer-s-treatments-as-failures-mount

Some notable excerpts include:

"U.S. drug regulators wants to let drugmakers test Alzheimer’s disease treatments on patients years before the disease shows outward signs, and could approve the therapies based on subtle biological signals rather than proof they alleviate symptoms."

"In the proposal, the FDA said it could quickly approve a drug for people who haven’t shown outward signs of Alzheimer’s, if the therapy affects a biological marker of the disease -- similar to how lowering blood pressure reduces the risk of a heart attack. Nothing like that currently exists for the disorder, which is the sixth-leading cause of death in the U.S."

"With a drug on the market under the fast-track process, a company would then have to conduct further trials to confirm that the biological change lead to a meaningful benefit, such as slowing patients’ initial decline in mental function, known as mild cognitive impairment."

"There are no approved Alzheimer’s treatments that slow progression of the disease, while almost 200 drugs have failed."